AWM
IOVA icon

Adams Wealth Management’s Iovance Biotherapeutics IOVA Stock Holding History

Adams Wealth Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,227
Closed -$52.9K – 162
2025
Q4 		$52.9K Hold
19,227
– – 0.01% 178
2025
Q3 		$42K Hold
19,227
– – 0.01% 181
2025
Q2 		$32.9K Hold
19,227
– – 0.01% 180
2025
Q1 		$63.3K Buy
+19,227
New +$99.2K 0.01% 142

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Adams Wealth Management's IOVA Position: Q1 2026 in Review

Adams Wealth Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 19,227 shares — an estimated $52.9K sold.

Adams Wealth Management first reported a position in IOVA in Q1 2025 and held it in 4 quarters. The position peaked at $63.3K in Q1 2025. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Adams Wealth Management reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Adams Wealth Management sold 19,227 Iovance Biotherapeutics shares in Q1 2026, an estimated $52.9K.
  • Adams Wealth Management first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 4 quarters.
  • Adams Wealth Management's Iovance Biotherapeutics position peaked at $63.3K in Q1 2025.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Adams Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.